{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:47:34Z","timestamp":1762145254771,"version":"build-2065373602"},"reference-count":24,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.bmcl.2017.04.036","type":"journal-article","created":{"date-parts":[[2017,4,13]],"date-time":"2017-04-13T21:45:48Z","timestamp":1492119948000},"page":"2313-2318","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Approaches towards the development of chimeric DPP4\/ACE inhibitors for treating metabolic syndrome"],"prefix":"10.1016","volume":"27","author":[{"given":"Jitendra A.","family":"Sattigeri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9907-2703","authenticated-orcid":false,"given":"Sachin","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph A.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahadat","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geeta V.","family":"Rayasam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Balasaheb G.","family":"Jadhav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satya M.","family":"Chilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dhrubajyoti","family":"Datta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Gadhave","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vamshi K.","family":"Tulasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarun","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sreedhara","family":"Voleti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biju","family":"Benjamin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunitha","family":"Udupa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garima","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yogender","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kona","family":"Srinivas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinay S.","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhijit","family":"Ray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pradip K.","family":"Bhatnagar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian A.","family":"Cliffe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2017.04.036_b0005","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1001\/jama.2017.0241","article-title":"Management of type 2 diabetes in 2017: getting to goal","volume":"317","author":"Reusch","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.bmcl.2017.04.036_h0010","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/01.HYP.23.2.145","volume":"23","year":"1994","journal-title":"Hypertension"},{"key":"10.1016\/j.bmcl.2017.04.036_h0015","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1161\/01.HYP.37.4.1053","article-title":"Diabetes, hypertension, and cardiovascular disease: an update","volume":"37","author":"Sowers","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.bmcl.2017.04.036_b0015","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200003303421301","article-title":"Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus","volume":"342","author":"Gress","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmcl.2017.04.036_h0025","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.1021\/jm058225d","article-title":"Designed multiple ligands. an emerging drug discovery paradigm","volume":"48","author":"Morphy","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2017.04.036_h0030","doi-asserted-by":"crossref","first-page":"8955","DOI":"10.1021\/jm400856t","article-title":"Polypharmacology \u2013 Foe or friend","volume":"56","author":"Peters","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2017.04.036_h0035","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nature01370","article-title":"Crystal structure of the human angiotensin-converting enzyme-lisinopril complex","volume":"421","author":"Natesh","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2017.04.036_h0040","doi-asserted-by":"crossref","first-page":"8718","DOI":"10.1021\/bi049480n","article-title":"Structural details on the binding of antihypertensive drugs captopril and enalaprilat to human testicular angiotensin I-converting enzyme","volume":"43","author":"Natesh","year":"2004","journal-title":"Biochemistry"},{"key":"10.1016\/j.bmcl.2017.04.036_h0045","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1021\/jm051283e","article-title":"Discovery, structure-activity relationship and pharmacological evaluation of (5-substituted-pyrrolidinyl-2-carbonyl)-2-cyanopyrrolidines as potent dipeptidyl peptidase IV inhibitors","volume":"49","author":"Pei","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2017.04.036_h0050","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1021\/jm0493156","article-title":"(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes","volume":"48","author":"Kim","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2017.04.036_b0035","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1021\/jm00401a014","article-title":"Angiotensin-converting enzyme inhibitors. Mercaptan, carboxyalkyl dipeptide, and phosphinic acid inhibitors incorporating 4-substituted prolines","volume":"31","author":"Krapcho","year":"1988","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2017.04.036_h0060","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.bmcl.2006.09.099","article-title":"(3R)-4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes","volume":"17","author":"Biftu","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2017.04.036_h0065","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1021\/jm070330v","article-title":"Discovery of potent and selective dipeptidyl peptidase IV inhibitors derived from \u03b2-aminoamides bearing substituted triazolopiperazines","volume":"51","author":"Kim","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2017.04.036_b0045","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2174\/156802607780091064","article-title":"Molecular recognition of ligands in dipeptidyl peptidase IV","volume":"7","author":"Kuhn","year":"2007","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.bmcl.2017.04.036_h0075","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1007\/BF02759631","article-title":"The synthesis of isomeric 4-prolinylamines and 4,4\u2032-diprolinylamines","volume":"26","author":"Yelin","year":"2000","journal-title":"Russ J Bioorg Chem"},{"key":"10.1016\/j.bmcl.2017.04.036_h0080","unstructured":"Dreher SD, Ikemoto N, Njolito E, Rivera NR, Tellers DM. Process to chiral beta- amino acid derivatives. WO 2004\/085661."},{"key":"10.1016\/j.bmcl.2017.04.036_h0085","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1016\/S0960-894X(01)80694-6","article-title":"4-Substituted proline derivatives that inhibit angiotensin converting enzyme and neutral endopeptidase 24.11","volume":"4","author":"Bhagwat","year":"1994","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2017.04.036_h0090","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1248\/cpb.37.280","article-title":"A practical and diastereoselective synthesis of angiotensin converting enzyme inhibitors","volume":"37","author":"Iwasaki","year":"1989","journal-title":"Chem Pharm Bull"},{"key":"10.1016\/j.bmcl.2017.04.036_h0095","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1038\/nprot.2006.305","article-title":"A high-throughput fluorimetric assay for angiotensin I-converting enzyme","volume":"4","author":"Schwager","year":"2006","journal-title":"Nat Protocols"},{"key":"10.1016\/j.bmcl.2017.04.036_h0100","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1042\/bj20021643","article-title":"Catalytic properties and inhibition of proline-specific depeptidyl peptidase II, IV and VII","volume":"371","author":"Leiting","year":"2003","journal-title":"Biochem J"},{"key":"10.1016\/j.bmcl.2017.04.036_h0105","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.2337\/diabetes.54.10.2988","article-title":"Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: Potential importance of selectivity over dipeptidyl peptidases 8 and 9","volume":"54","author":"Lankas","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.bmcl.2017.04.036_h0110","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.bcp.2005.04.009","article-title":"Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by vildagliptin ((2S)-{[3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile)","volume":"70","author":"Brandt","year":"2005","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bmcl.2017.04.036_b0065","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1021\/jm030091l","article-title":"1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties","volume":"46","author":"Villhauer","year":"2003","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2017.04.036_b0070","unstructured":"All the molecular modeling calculations (ligand preparation, protein preparation and molecular docking) were performed using modules available within the SYBYL7.3 suite of programs. SYBYL, Tripos Inc., www.tripos.com."}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X17304158?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X17304158?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:17:42Z","timestamp":1760771862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X17304158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0960894X17304158"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2017.04.036","relation":{},"ISSN":["0960-894X"],"issn-type":[{"type":"print","value":"0960-894X"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Approaches towards the development of chimeric DPP4\/ACE inhibitors for treating metabolic syndrome","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2017.04.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}